GlassScriptPhysician profile
Rodolfo E Vicente
NPI 1881702868
$1,585.66
in general payments reported to CMS, 2019-2025
20 companies · $595 in 2025
The $595 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $153 · 2023: $335 · 2024: $503 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $244.63 | 2024-2025 | Zurzuvae |
| Abbvie INC. | $174.64 | 2022-2025 | Lo Loestrin Fe, Orilissa |
| Optumhealth Care Solutions, LLC | $170.77 | 2023-2024 | Vivify Health Care Team Portal 001, Eitan Medical, Zyno Solutions |
| Shield Therapeutics INC | $153.79 | 2025 | |
| Mayne Pharma Commercial LLC | $138.60 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $124.46 | 2023-2025 | Myfembree |
| Organon LLC | $103.49 | 2022-2025 | Nexplanon |
| Dexcom, INC. | $80.81 | 2024-2025 | Dexcom G6 Transmitter |
| Agile Therapeutics, INC. | $62.86 | 2023-2024 | Twirla |
| Hologic Sales and Service, LLC | $50.95 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $47.55 | 2023-2024 | |
| Supernus Pharmaceuticals, INC. | $41.55 | 2025 | Qelbree |
| Livanova USA, INC. | $35.37 | 2022-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Pfizer INC. | $32.65 | 2022-2024 | |
| Astellas Pharma US INC | $30.51 | 2024 | Veozah |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $29.87 | 2025 | Slynd |
| Therapeuticsmd, INC. | $17.10 | 2022 | |
| Verrica Pharmaceuticals INC. | $16.44 | 2024 | Ycanth |
| Evofem Biosciences, INC. | $14.94 | 2023 | Phexxi |
| Biohaven Pharmaceutical Holding Company LTD. | $14.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodolfo Vicente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.